Henry Schein Dental Company is a leading provider of dental products and services, catering primarily to dental professionals and practices
The company offers a comprehensive range of solutions including dental equipment, consumable supplies, technology products, and practice management tools. In addition to its product offerings, Henry Schein Dental also provides training and support services, helping dental practitioners enhance their operations and improve patient care. With a strong emphasis on innovation and customer service, the company plays a vital role in advancing the dental industry and supporting the success of dental health providers.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Henry Schein (NASDAQHSIC) and the best and worst performers in the dental equipment & technology industry.
Dental and medical products company Henry Schein (NASDAQHSIC) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 5.8% year on year to $3.19 billion. Its non-GAAP profit of $1.19 per share was 1.6% below analysts’ consensus estimates.
Henry Schein has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.3% to $77.62 per share while the index has gained 12.2%.
The private equity firm will also be able to purchase additional shares via open market purchases, up to a total equity stake of 14.9% in Henry Schein.
BofA sees 2025 challenges for healthcare tech and distributors but upgrades Cardinal Health and Henry Schein, highlighting growth and recovery potential.
Patient Square Capital agrees to buy Patterson Companies for $4.1 billion. Analysts predict minimal regulatory hurdles and a strong bid unlikely to face competition.
